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Lactatemia during treatment of status asthmaticus in children 
 
INTRODUCTION 
Asthma is a chronic inflammatory disorder of the 
airways in which many cells and cellular elements 
play a role, in particular mast cells, eosinophils, T-
lymphocytes, neutrophils, and epithelial cells. In 
susceptible individuals, this inflammation causes 
recurrent episodes of wheezing, breathlessness, 
chest tightness, and cough particularly at night 
and/or in the early morning. These episodes are 
usually associated with widespread but variable 
airflow obstruction that is often reversible either 
spontaneously or with treatment. The inflammation 
also causes an associated increase in the existing 
bronchial hyperresponsiveness to a variety of 
stimuli1. 
In the New Children's Hospital of Cairo 
University, respiratory illnesses were the most 
frequent cause of admission (20.6%) and bronchial 
asthma constituted 8.6% of them2. β2-agonists 
remain the mainstay of therapy for acute asthma 
and, for most patients, standard doses are 
acceptable3. Lactic acidosis is infrequently reported 
in children with status asthmaticus, although it has 
been documented4,5. Transient increase of lactate 
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contributing factors. 
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most cases. Prediction of lactic acidosis prevents inappropriate 
intensification of therapy especially in patients with more severe attacks or 
impending respiratory failure. 
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levels (lactatemia) has been seldom observed as a 
complication of β-adrenergic agents administered 
during an asthma attack6. Our aim through this 
work is to detect the incidence of lactatemia in 
children with acute asthma treated with nebulized 
β2-agonists, and to delineate its causes and effects 
on the patient’s prognosis. 
   
METHODS 
The study included 32 asthmatic children (22 males 
and 10 females), their ages ranged from 6 to 8 years 
with a mean of 6.48±0.68 years. Intermittent asthma 
was diagnosed in 68.8% of patients while 31.2% of 
them had mild persistent asthma. The duration of 
their disease ranged from 2-6 years with a mean of 
3.8±1 years. They were referred over the period 
from October to December 2003 to the emergency 
department of Cairo University Children's Hospital 
because of acute asthma exacerbation. 
All patients were subjected to the following: 
1. Complete history taking especially for the 
duration of disease, frequency of acute attacks, 
nocturnal symptoms, precipitating factors, and 
drug therapy. 
2. Clinical examination with special reference to the 
mental status, vital signs, criteria of respiratory 
distress, and chest signs. 
3. Peak Expiratory Flow Rate (PEFR) was done 
after initial bronchodilator therapy using a 
portable Mini-Wright Peak Flow Meter. 
4. Laboratory investigations: 
• Complete blood and differential count (CBC) 
using the ADVIA 120 cell counter (Bayer 
Diagnostics, Ireland). 
• Total serum IgE was determined by the ELISA 
(International Immuno-Diagnostics, USA). 
• Blood gases were done before, and 1 h after 
nebulized salbutamol therapy using IL 
International (Japan). 
• Plasma lactate level was determined7 using the 
Randox kit. Samples for lactate levels were taken 
before treatment [H0], 1 h [H+1], and 24 h 
[H+24] after treatment with nebulized salbutamol. 
After assessment, patients were divided into 2 
groups according to the severity of their asthma 
attacks: those with severe attacks (20 patients, 
62.5%), and those with moderate attacks (12 
patients, 37.5%). All patients received nebulized 
salbutamol up to 3 doses at 20 minutes intervals 
(0.1 mg/kg/dose, minimum 2.5 mg, mixed with 
normal saline to final volume 3-4 ml) together with 
O2 at 6-7 L/min. IV hydrocortisone was used after 
the first 40 minutes for patients showing incomplete 
response to salbutamol, while ipratropium bromide 
was added after the 1st hour if needed. Theophylline 
was not used in the management of our patients 
during their acute attacks. 
 
Statistical methods: 
Results were analyzed and statistically compared 
using the 9th version of the statistical package SPSS. 
Qualitative data were presented as numbers and 
percentages, and chi-squared test [χ2] was used for 
comparison between each two variables. The 
quantitative data were described as mean±SD, and 
range. The student’s [t-test] was used to compare 
between each two groups. Pearson’s correlation 
coefficient [r] was used to evaluate the relations 
between the studied numerical variables. The p-




From history taking in our series, spring was the 
highest season for the occurrence of asthma 
exacerbations (65.6%). The precipitating factors for 
asthma symptoms include irritants (96.9%), viral 
upper respiratory infections (84.4%), chemicals 
(59.4%), food (12.5%), and exercise (6.3%). 
Concerning the associated atopic disorders, 75% of 
patients had at least one atopic disease [allergic 
rhinitis was the most prevalent, it was present alone 
or with other atopic disorders in 93.7% of patients], 
while 25% of patients had two atopic diseases. 
Other atopic diseases encountered in our patients 
were allergic conjunctivitis and atopic dermatitis. 
Considering current medications; inhaled steroids 
were not prescribed to any of our mild persistent 
asthmatic children, but only a combination of oral 
drugs e.g. β2-agonists, theophylline. Six of our 
patients were using oral steroids during their current 
acute attack [data not shown]. 
Table [1] and Figures [1, 2] showed marked and 
statistically highly significant improvement in the 
degree of wheezing, vital signs, and blood gas 
parameters of our patients at H+1 after nebulized 
salbutamol therapy. This improvement was equally 
highly significant in patients with either moderate 
or severe asthma attacks (p < 0.001 compared to 
that at H0 for all parameters). 
Table [2] and Figure [3] demonstrated that 
plasma lactate levels on admission and before 
treatment were within the normal values in all 
patients [1.35±0.38 mmol/L]. One hour after 
starting nebulized salbutamol, a highly significant 
rise in plasma lactate occurred [4.44±0.78 mmol/L, 
p < 0.001 vs H0]. Twenty-four hours after starting 
treatment plasma lactate levels had returned to 
normal values in all patients’ groups [although 
slightly higher than the H0 levels] (1.91±0.59 
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mmol/L, p < 0.001 for the comparison between 
each of the H0 vs H+1, H+1 vs H+24, and H0 vs 
H+24). 
Considering various degrees of asthma severity, 
no significant difference in the H0 plasma lactate 
was observed between patients with severe or 
moderate attacks (a mean of 1.37±0.38 and 
1.32±0.4 mmol/L respectively, p = 0.7). On the 
other hand, plasma lactate was elevated to a greater 
degree at H+1 in patients with severe attacks 
compared to those with moderate attacks (a mean of 
4.69±0.8 and 4.02±1.6 mmol/L respectively, p < 
0.05). 
Our work demonstrated that the rise in plasma 
lactate levels at H+1 was significantly more 
obvious in patients currently using oral steroids 
before enrollment compared to non-users (a mean 
of 5.11±0.89 and 4.28±0.68 mmol/L respectively, p 
< 0.05) [data not shown]. 
Table [3] showed the different correlations 
done between plasma lactate and various patients’ 
data. There were statistically significant positive 
correlations between the respiratory rate [both at H0 
and H+1] and plasma lactate level at H+1 (r = 0.44, 
0.47 respectively, p < 0.05). Also, total serum IgE 
showed a statistically significant positive 
correlation with the plasma lactate level at H+1 (r = 
0.44, p < 0.05). 
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a p-value ≤ 0.05 is considered significant. 
PaCO2: Arterial CO2 tension. PaO2: Arterial O2 tension. SaO2: Arterial O2 saturation. SD: Standard deviation.  
 
















a p-value ≤ 0.05 is considered significant. SD: Standard deviation. 
*Pre-treatment vs 1 h post-treatment, 1 h post-treatment vs 24 h post-treatment, and pre-treatment vs 24 h post-treatment. 
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H.R.: heart rate; R.R.: respiratory rate. 
Figure 1. Vital signs before and after treating asthmatic exacerbations of the children. 
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PaCO2: Arterial CO2 tension; PaO2: Arterial O2 tension; SaO2: Arterial O2 saturation. 
Figure 2. Blood gases before and after treating asthmatic exacerbations of the children. 
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Figure 3. Plasma lactate before and after treating exacerbations of asthma in the studied sample. 
 
 




Pre-Treatment 1 h Post-Treatment 24 h Post-Treatment 
r a p r a p r a p 
Age - 0.16 NS 0.06 NS - 0.22 NS 
Duration of asthma - 0.09 NS 0.16 NS - 0.23 NS 
PEFR (after initial bronchodilator) - 0.21 NS - 0.06 NS - 0.23 NS 
Respiratory rate 
     Pre-treatment 
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Total s IgE (pre-treatment) 0.20 NS 0.44 < 0.05 0.08 NS 
PaO2 
     Pre-treatment 
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a p-value ≤ 0.05 is considered significant, NS = not significant. 
PaCO2: Arterial CO2 tension. PaO2: Arterial O2 tension. PEFR: Peak expiratory flow rate. SaO2: Arterial O2 saturation. Total s IgE: 
Total serum immunoglobulin E. 
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DISCUSSION 
Lactic acidosis is a well described phenomenon in 
adults with severe exacerbations of asthma8,9. 
However this entity is infrequently reported in 
children with status asthmaticus, although it has 
been documented4,5. 
On admission to the emergency department 
[H0], all our patients had normal lactate levels. 
These levels were slightly higher in patients with 
severe exacerbations compared to those with 
moderate attacks; this difference was statistically 
not significant. Also, the baseline lactate levels 
were slightly higher in patients with mild persistent 
asthma compared to those with intermittent asthma; 
the difference was again statistically not significant. 
One hour post-treatment, all patients developed 
appreciable lactatemia representing a 257±121.5% 
increase above the H0 levels. In patients with 
severe attacks the increase in plasma lactate was 
significantly higher than in those with moderate 
attacks. Also, patients with mild persistent asthma 
showed a higher mean lactate level at H+1 
compared to those with intermittent asthma. 
Our results are in agreement with data provided 
by Rabbat et al.10 who reported hyperlactatemia in 
all patients during the course of treatment. On the 
other hand, our results contradict those of Yousef 
and McGeady5 who demonstrated lactic acidosis in 
only 1% of pediatric patients admitted to the ICU 
with status asthmaticus. The timing of 
determination of lactate levels could explain this 
discrepancy in the frequency of hyperlactatemia in 
various published studies. 
The pathogenesis of lactic acidosis in asthma is 
not well understood. Yousef and McGeady5 stated 
that this phenomenon may be caused by lactate 
accumulation (through excessive production, and 
inadequate clearance) together with the loss of 
bicarbonate. Excess lactate production in acute 
asthma exacerbation may be multifactorial and 
attributable to overuse of respiratory muscles under 
hypoxic conditions, reduced tissue perfusion, and 
administration of β-agonists and glucocorticoids. 
However, in the case-report studies by Maury et al.8 
and Manthous9, increased work of breathing has 
been excluded as a factor in producing lactic 
acidosis. 
In our work, while lactate levels were rising; 
bronchial obstruction was improving as evidenced 
by the statistically highly significant (p < 0.001) 
improvement of clinical as well as blood gas 
parameters at H+1. These findings preclude 
overworked respiratory muscles as a cause of 
lactatemia, and they go hand-in-hand with previous 
reports5,8,9. However, they are not in accordance to 
observations made by Appel and colleagues11 who 
noticed that the development of lactic acidosis was 
associated with persistent severe obstruction of 
expiratory airflow. 
Hypoxemia and tissue hypoxia have been 
hypothesized as pathogenetic factors precipitating 
lactic acidosis in asthma12. In our series, all patients 
were hypoxemic at presentation and the SaO2 was 
below 90% in a quarter of them. At that time [H0], 
plasma lactate levels were normal. At H+1 
hyperlactatemia appeared despite a significant 
improvement in SaO2, and this excludes hypoxemia 
as a contributing factor in lactatemia during 
treatment of acute asthma exacerbations. 
Glucocorticoids are known to enhance the 
sensitivity of β-receptors to β-adrenergic agents, 
and could sometimes contribute to lactic acidosis 
when used during treatment of acute asthma 
attacks13. However, as the onset of action of 
systemic glucocorticoids is reported to be 4-6 
hours14; the significant difference noted in lactate 
levels at H+1 between the groups of our patients 
using or not using oral glucocorticoids was thus 
mostly attributed to current oral glucocorticoids use 
before enrollment in the study and not due to the IV 
hydrocortisone given to these patients. This finding 
is in agreement with the observation reported by 
Stratakos and colleagues6. They stated that transient 
increase of lactate levels with or without metabolic 
acidosis has been seldom reported as a complication 
of β-adrenergic agents administered during an 
asthmatic attack. On the other hand, many other 
workers have linked the use of β-adrenergic 
agonists with the occurrence of lactatemia4,5,10,15. 
In our work, all patients received the same 
treatment regimen during the first 40 minutes and 
all of them developed lactatemia, thus a potential 
effect of treatment must be questioned16. None of 
our patients had received IV bronchodilators 
including theophylline, so nebulized salbutamol 
used for all patients can be strongly accused as the 
pathogenetic factor that might account for 
lactatemia. 
The mechanisms by which β2-agonists may 
cause lactic academia are proposed to be through 
β2-receptor activation with consequent enhanced 
glycogenolysis and lipolysis4,16. Increased 
glycogenolysis eventually leads to increased 
concentrations of pyruvate. Pyruvate is converted to 
acetyl-CoA, which enters the citric acid cycle. If 
pyruvate does not enter this aerobic pathway, it is 
converted to lactate instead, thereby potentially 
causing lactic acidosis. In addition, an increased 
lipolysis also increases acetyl-CoA through a 
different pathway. An increased acetyl-CoA 
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concentration potentially inhibits pyruvate 
oxidation to acetyl-CoA and leads to excess 
pyruvate. Finally, β2-receptor stimulation will also 
inhibit the pyruvate dehydrogenase complex, and 
this might further limit the rate of pyruvate 
oxidation to acetyl-CoA16. 
Concerning the effects of lactatemia on clinical 
indices of severity of asthma exacerbation, our 
results demonstrated that at H+1; while lactate 
levels were rising, there was a statistically highly 
significant improvement in the respiratory rate and 
heart rate (Table 1). Much improvement occurred in 
patients with moderate attacks compared to those 
with severe attacks. Our data are different from 
those reported by Maury et al.8, and from the case-
report by Yousef and McGeady5 who noticed 
persistent hyperpnea with Kussmaul breathing 
despite the continuous nebulized albuterol therapy. 
This could be due to the metabolic acidosis present 
in the latter case. Also, lactate levels of our patients 
were related to the degree of dyspnea. A 
statistically significant positive correlation was 
observed between lactate levels at H+1 and the 
respiratory rate (Table 3). 
Our findings demonstrate that lactate levels at 
H+24 returned to normal values in most of the 
patients and this was in parallel with the reduction 
in the frequency of nebulized salbutamol. No 
significant difference was observed in lactate levels 
at H+24 between patients with severe attacks 
compared to those with moderate attacks. 
None of our patients developed metabolic 
acidosis, and all of them showed significant clinical 
improvement during the first 24 hours of treatment. 
This is in agreement with the work of Rabbat et 
al.10 who stated that hyperlactatemia seems to have 
no prognostic value in acute severe asthma, and 
metabolic acidosis with an increased anion gap was 
present in only 14% of their patients. Also, Yousef 
and McGeady5 did not find lactic acidosis in 
pediatric patients with status asthmaticus who 
developed respiratory failure. 
From this study we conclude that delayed 
lactatemia is a common finding during treatment of 
acute severe asthma in children, however it is not 
predictive of bad prognosis or respiratory failure. 
Those who care for children and adolescents with 
status asthmaticus should be aware of lactatemia as 
a side effect of β2-agonist treatment, observe 
carefully for unexplained acidosis, rising anion gap, 
or evidence of resistance to bronchodilator therapy. 
Identification of lactic acidosis prevents the 
inappropriate intensification of treatment regimen 
especially in patients with severe attacks or 
imminent respiratory arrest. Other factors that 
might be sharing in the occurrence of lactatemia 
remain to be explored. These include the 
hemodynamic disturbances occurring during acute 
severe asthma, and the effects of plasma 
catecholamine and phosphate levels. 
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